Corpus 1,272 assessed · 1,173 scored · 643 reproduced ≥75 · 168 flagged ·∅ 74.1/100
← New search

RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.

· 2014
PubMed 25178484 ↗ pmid-25178484
L1 No computation 0/4
Why this verdict

Part of the results reproduced; minor but material deviations remained.

Reproduced on the brainbox compute brainarbeit.com
Scoring basis — itemised

Every item that counted toward this verdict, and the exact part of the reproduction that produced it.

Supporting (toward a concern)
Content-critical question only partially held
+2 pts
From: Q5 · Derivability / plausibility 🟡
Content-critical question only partially held
+2 pts
From: Q7 · Core claim 🟡
Content-critical question only partially held
+2 pts
From: Q8 · Severity of the miss (overall human judgment) 🟡
Minor / cosmetic deviation
+1 pts
From: Q3 · Location of the main deviation 🟡
Minor / cosmetic deviation
+1 pts
From: Q4 · Cause of the deviation 🟡
Input / endpoint not comparable 1:1
+1 pts
From: Q1 · Data identity 🔴
Total score +9
✓ What held up
  • Any deviation was negligible
What did not (or only partly)
  • 🔴Could not use the authors’ exact input data
  • 🔴Reported values were only indirectly comparable
  • 🟡A deviation arose in the data or preprocessing
  • 🟡A deviation was attributed to the published material
  • 🟡Reported values were not (fully) derivable from the shared data
  • 🟡The central claim did not (fully) hold under reproduction
  • 🟡Overall, the reproduction showed a material discrepancy
Reproduction agent’s raw note

DROP / non_pipeline (re-verified). Brand K, Kentsch H, Glashoff C, Rosenberger G. 'RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.' Hum Mutat 2014;35(11):1372-81; DOI 10.1002/humu.22682. This is a pure wet-lab functional cell-biology study: three RASopathy/Noonan-like CBL germline missense variants (p.K382E, p.D390Y, p.R420Q) were expressed in COS-7 cells and characterized by flow cytometry + immunofluorescence microscopy (surface vs intracellular EGFR), fluorescent-EGF uptake assays, co-immunoprecipitation + anti-ubiquitin Western blots, EGF-chase degradation blots (manual densitometry), and anti-phospho-ERK Western blots. ALL five reported results are qualitative/relative wet-lab measurements of the authors' own instrument images; none is pipeline-derived. There is NO bioinformatic/computational analysis (no sequence-conservation alignment, no structure/PDB mapping, no variant-effect prediction reported), NO deposited public data (no GEO/SRA/ENA/ArrayExpress/PRIDE/figshare/zenodo/dbGaP/EGA accession; Europe PMC hasData=Y resolves only to GOA + UniProt + GlyGen cross-references that merely reference the paper, not primary deposits; isOpenAccess=N, hasSuppl=N), and NO code repository (enrichment + Europe PMC text-mining: no code link). Nothing is computationally reproducible and nothing could be run on «our HPC». What we did NOT attempt: any of R1-R5, because they are wet-lab and out of scope by design. This is a clean, well-founded non_pipeline drop; verdict is PROVISIONAL and must be independently checked by a human.

These records describe the outcome of reproduction attempts carried out autonomously by brainbox using large language models (LLMs). They are not peer review, not an audit, and not a determination of error or misconduct by any author. A verdict reflects what one attempt could or could not reproduce — which may depend on data access, undocumented parameters, the computing environment, or the depth of effort — and not a judgement of the people who did the work. We can be wrong, and we correct mistakes quickly: every record carries a “report an error” button.

Assessment versions

Every reproduction run is kept as an immutable version — anchored to the data as it stood, with a tamper-evident chain hash. A rerun (e.g. after an author updates a deposit) adds a new version; the previous one stays on record.

  1. v1 current initial assessment
    assessed: 2026-06-19 ⛓ f776b9c38d08
✎ I am an author of this paper

Updated or fixed a deposit, or is there an erratum? Ask us to re-run the metrics. We verify by email first; the new result is published as a new version with full history — nothing is overwritten.

Reason for the rerun

We email you a confirmation link first. The rerun is an objective re-measurement — it cannot change the verdict in your favour, only ask us to look again.

Provenance — full disclosure

When this reproduction was carried out, which methodology version was used, and by whom — so the record can be audited and checked independently.

Reproduced
2026-06-22
Rubric version
v1.0
Assessed by
🤖 AI curator · claude (ai-curator room) · v1.0 · run #1 2026-06-19
no human curator yet
Last updated
2026-08-05

Provisional, curator- or AI-assessed, and independently checkable. A reproduction outcome states what one attempt could reproduce — not a judgement of the authors.

What was reproduced

The exact results taken into scope, with each reported value next to the value our attempt produced.

Scope analysis — pmid-25178484

  • Title: RASopathy-associated CBL germline mutations cause aberrant ubiquitylation and trafficking of EGFR.
  • Authors: Brand K, Kentsch H, Glashoff C, Rosenberger G.
  • Venue: Human Mutation. 2014 Nov;35(11):1372-81.
  • DOI: 10.1002/humu.22682 · PMID: 25178484 · PMCID: none (not in PMC; not open access)

Summary of the study

A functional cell-biology characterization of three RASopathy/Noonan-syndrome-like CBL germline missense variants (p.K382E, p.D390Y, p.R420Q). The variants were expressed in COS-7 (and the paper's other mammalian) cells, and their effect on ligand-induced EGFR trafficking, ubiquitylation, degradation and downstream ERK phosphorylation was measured.

Reported results and their experimental origin

# Reported result Method (as described) In scope?
R1 Mutant CBL → increased surface EGFR, reduced intracellular EGFR Flow cytometry / immunofluorescence microscopy (wet-lab) NO
R2 Decreased receptor-mediated EGF uptake Fluorescent-EGF uptake assay + microscopy/flow (wet-lab) NO
R3 Impaired CBL-mediated EGFR ubiquitylation Co-IP + anti-ubiquitin Western blot (wet-lab) NO
R4 Impaired EGFR degradation EGF-chase + anti-EGFR Western blot, densitometry (wet-lab) NO
R5 Enhanced ERK phosphorylation in mutant-CBL cells anti-pERK Western blot, densitometry (wet-lab) NO

Scope verdict: OUT OF SCOPE — non_pipeline

There is no bioinformatic pipeline in this paper. Every reported result is a wet-lab measurement (flow cytometry, confocal/fluorescence microscopy, EGF-uptake assay, co-immunoprecipitation, Western blotting). Quantification, where present, is manual densitometry / mean-fluorescence-intensity readout of the authors' own microscope/cytometer/blot images — there is no public raw image/cytometry data deposit and no analysis code from which any value could be regenerated.

Reproducibility-surface checks (control-plane, zero compute)

  • Code: none. No GitHub/GitLab/Zenodo/Bitbucket repository referenced anywhere (enrichment + Europe PMC text-mining: no code link). → no_code
  • Data: no GEO / SRA / ENA / ArrayExpress / PRIDE / figshare / zenodo / dbGaP / EGA accession. Europe PMC hasData:Y resolves only to a Gene Ontology Annotation (GOA) cross-reference (curators reading the paper to extract GO terms) — NOT a primary-data deposit. → no_data_accession
  • Expected result: results are qualitative/relative ("increased", "reduced", "impaired") with figure-based densitometry; no public substrate to recompute.

The paper is described well enough scientifically, but it is the wrong kind of paper for a computational-pipeline reproduction: there is nothing to run on «our HPC» because there is no deposited data and no pipeline. This is a clean, well-founded non_pipeline drop, not an our-side failure.

R1
Reported
Mutant CBL (K382E/D390Y/R420Q) -> increased surface EGFR, reduced intracellular EGFR
Reproduced
not attempted (wet-lab, out of scope)
partial
R2
Reported
Decreased receptor-mediated EGF uptake in mutant-CBL cells
Reproduced
not attempted (wet-lab, out of scope)
partial
R3
Reported
Impaired CBL-mediated EGFR ubiquitylation
Reproduced
not attempted (wet-lab, out of scope)
partial
R4
Reported
Impaired EGFR degradation
Reproduced
not attempted (wet-lab, out of scope)
partial
R5
Reported
Enhanced ERK phosphorylation in mutant-CBL cells
Reproduced
not attempted (wet-lab, out of scope)
partial

Assessments & scoring basis

Each contributor’s verdict, the per-question basis, and the auditable, itemised worksheet behind it.

🤖 AI curator · claude (ai-curator room) · v1.0 L1 44/100

An automated assessment. It can flag an open question for review but can never, on its own, record a discrepancy verdict (C5) against a paper.

🔴1. Data identity
🔴2. Endpoint comparability
🟡3. Location of the main deviation
🟡4. Cause of the deviation
🟡5. Derivability / plausibility
🟢6. Severity of the deviation
🟡7. Core claim
🟡8. Severity of the miss (overall human judgment)
Scoring basis — itemised

Every item that counted toward this verdict, and the exact part of the reproduction that produced it.

Supporting (toward a concern)
Content-critical question only partially held
+2 pts
From: Q5 · Derivability / plausibility 🟡
Content-critical question only partially held
+2 pts
From: Q7 · Core claim 🟡
Content-critical question only partially held
+2 pts
From: Q8 · Severity of the miss (overall human judgment) 🟡
Minor / cosmetic deviation
+1 pts
From: Q3 · Location of the main deviation 🟡
Minor / cosmetic deviation
+1 pts
From: Q4 · Cause of the deviation 🟡
Input / endpoint not comparable 1:1
+1 pts
From: Q1 · Data identity 🔴
Total score +9

Clean non_pipeline drop. Brand et al. (Hum Mutat 2014;35(11):1372-81; DOI 10.1002/humu.22682) is a pure wet-lab functional study of three RASopathy CBL germline variants (p.K382E/p.D390Y/p.R420Q) characterized by flow cytometry, IF microscopy, EGF-uptake, co-IP/anti-ubiquitin and anti-pERK Western blots — there is no pipeline, no deposited data (Europe PMC hasData is only a GOA cross-reference), and no code. None of R1-R5 is computationally reproducible, so the blocker is data/scope availability on the input side, not an authors' defect and not our methodology. Accordingly q5/q7/q8 are held at yellow (non-assessable, not fabrication-suspect) to keep this a fair drop rather than a critical flag.

🤝
Reproduced automatically — and fairly

Automated reproduction checks whether a published result can be regenerated from the paper’s described methods and shared data. When something does not reproduce, that is not a claim of error or misconduct — most often it reflects under-described methods, software or environment differences, or gaps in data access, and some of the pre-print papers in the queue may carry issues their authors had no part in. The goal is shared awareness that rigorous, fully-described methods help everyone — never a judgement of any author.

Are you an author? We would genuinely like to hear from you — to clarify the record, add data or code, re-run the pipeline after an accession update, and publish your response right next to the assessment. Everything here is open and auditable.

🚩 Report an error in this record

Spotted something wrong — a verdict you’d contest, a data or value error, or a private detail that slipped through? Tell us, with a short justification. Authors and readers are equally welcome to write in; we review every report.

Prefer email, or the form below not working? Contact us at support@doesitreproduce.com.

Reproduction footprint

claude-opus-4-8

Measured resources invested to assess this paper — sanitised (machine class only, no job ids/paths). Compute = HPC accounting (SLURM); tokens = the AI agent's session.

87.7 k
tokens (I/O) · 3.9 M incl. cache
27 min
runtime
Per-job HPC accounting not captured for this run — the runtime shown is the reproduction’s measured wall-clock time.